Biotheus’ Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-ß bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Adminis...

Full "IntellAsia: Resources" article